To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease

European Archives of Psychiatry and Clinical Neuroscience

Volumn 259, Issue 4, 2009, Pages 248-256

  Diniz, Breno Satler ^a   Pinto Jr , Jony Arrais ^a   Gonzaga, Maria Luiza Cavichioli ^a   Guimarães, Fabiana Meira ^a   Gattaz, Wagner Farid ^a   Forlenza, Orestes Vicente ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Disease modifying therapies; Mild cognitive impairment; Progression; Treatment

Indexed keywords

DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA BASE; DEMENTIA; DISEASE COURSE; HUMAN; LONG TERM CARE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 67349214444     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-008-0864-1     Document Type: Article

References (50)

1. [No author listed] (2004) Efficacy and safety of rivastigmine in patients with mild cognitive impairment. NCT00134953. Available on-line on http://www.clinicaltrials.gov/ct2/show/NCT00134953 . Accessed 27 Oct 2008
2. [No author's listed]. (2007) A randomized double blind parallel, placebo-controlled trial to examine the efficacy of oral donepezil (5 mg qd for 6 weeks) after single dose and steady state therapy (2 and 6 weeks) in subjects with mild cognitive impairment. NCT00483028. Available on-line on http://clinicaltrials.gov/ct2/show/NCT00483028 . Accessed 27 Oct 2008
3. [No authors listed] (2004) Cognitive enhancers explored with PET imaging. NCT 00042172. Available on-line http://clinicaltrials.gov/ct2/show/NCT00042172 . Accessed 27 Oct 2008
4. D Ames RC Petersen DS Knopman PJ Visser H Brodaty S Gauthier 2006 Is mild cognitive impairment a clinically useful concept? Int Psychogeriatr 18 393 414
5. Anita M (2007) A one-year, multicenter, randomized, double-blind, placebo controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment. NCT00293176. Available on line http://clinicaltrials.gov/ct2/show/NCT00293176 . Accessed 27 Oct 2008
6. L Bäckman BJ Small L Fratiglioni 2001 Stability of the preclinical episodic memory deficit in Alzheimer's disease Brain 124 96 102 (Pubitemid 32055992)
7. R Brookmeyer E Johnson K Ziegler-Graham HM Arrighi 2007 Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 186 191 (Pubitemid 46825511)
8. JD Buxbaum M Oishi HI Chen R Pinkas-Kramarski EA Jaffe SE Gandy P Greengard 1992 Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor Proc Natl Acad Sci USA 89 10075 10078
9. JL Cummings R Doody C Clark 2007 Disease-modifying therapies for Alzheimer disease: challenges to early intervention Neurology 69 1622 1634 (Pubitemid 350287147)
10. BS Diniz JA Pinto Jr OV Forlenza 2008 Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature World J Biol Psychiatry 9 172 182
11. R Doody D Geldmacher B Gordon CA Perdomo RD Pratt Donepezil Study Group 2001 Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease Arch Neurol 58 427 433 (Pubitemid 32217459)
12. B Dubois HH Feldman C Jacova ST Dekosky P Barberger-Gateau J Cummings A Delacourte D Galasko S Gauthier G Jicha OJ Meguro F Pasquier P Robert M Rossor S Salloway Y Stern PJ Visser P Scheltens 2007 Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 734 746 (Pubitemid 47058377)
13. GG Farias JA Godoy F Hernandez J Avila A Fisher NC Inestrosa 2004 M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity: a role for Wnt signaling pathway Neurobiol Dis 17 337 348 (Pubitemid 39345789)
14. HH Feldman S Ferris B Winblad N Sfikas L Mancione Y He S Tekin A Burns J Cummings T del Ser D Inzitari JM Orgogozo H Sauer P Scheltens E Scarpini N Herrmann M Farlow S Potkin HC Charles NC Fox R Lane 2007 Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study Lancet Neurol 6 501 512 (Pubitemid 46738627)
15. OV Forlenza E Chiu 2008 Mild cognitive impairment: a concept ready to move on? Curr Opin Psychiatry 21 529 532
16. OV Forlenza JM Spink R Dayanandan BH Anderton OF Olesen S Lovestone 2000 Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons J Neural Transm 107 1201 1212
17. O Hansson H Zetterberg P Buchhave E Londos K Blennow L Minthon 2006 Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 228 234 (Pubitemid 43238346)
18. M Hashimoto H Kazui K Matsumoto Y Nakano M Yasuda E Mori 2005 Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162 676 682 (Pubitemid 40489128)
19. C Hooper R Killick S Lovestone 2008 The GSK3 hypothesis of Alzheimer's disease J Neurochem 104 1433 1439
20. AR Jadad A Moore D Carroll C Jenkinson JM Reynolds DJ Gavaghan HJ McQuay 1996 Assessing the quality of reports of randomized clinical trials: is blinding necessary Controlled Clin Trials 17 1 12 (Pubitemid 26120810)
21. J Koontz A Baskys 2005 Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study Am J Alzheimers Dis Other Demen 20 295 302 (Pubitemid 41502371)
22. ESC Korf LO Wahlund PJ Visser P Scheltens 2004 Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment Neurology 63 94 100 (Pubitemid 38943785)
23. KL Lanctôt N Herrmann KK Yau LR Khan BA Liu MM LouLou TR Einarson 2003 Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis CMAJ 169 557 564 (Pubitemid 37174596)
24. T Leyhe E Stransky GW Eschweiler G Buchkremer C Laske 2008 Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease Eur Arch Psychiatry Clin Neurosci 258 124 128
25. S López-Pousa A Turon-Estrada J Garre-Olmo I Pericot-Nierga M Lozano-Gallego M Vilalta-Franch M Hernández-Ferràndiz V Morante-Muñoz A Isern-Vila E Gelada-Batlle J Majó-Llopart 2005 Differential efficacy of treatment with cholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period Dement Geriatr Cogn Disord 19 189 195 (Pubitemid 40522806)
26. RW Mahley KH Weisgraber Y Huang 2006 Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease Proc Natl Acad Sci USA 103 5644 5651
27. Mendes 2008 Lithium reduces Gsk3b mRNA levels implications
28. National Institute for Clinical Excellence (NICE) (2004) Management of depression in primary and secondary care. The British Psychological Society and Gaskel. Leicester
29. RM Nitsch BE Slack RJ Wurtman JH Growdon 1992 Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors Science 28 304 307
30. RC Petersen 2006 Conversion Neurology 67 Suppl. 3 s12 s13 (Pubitemid 44684671)
31. RC Petersen 2007 MCI treatment trials: failure or not? Lancet Neurol 6 473 475 (Pubitemid 46734762)
32. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen 1999 Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 303 308 (Pubitemid 29120227)
33. RC Petersen RG Thomas M Grundman D Bennett R Doody S Ferris D Galasko S Jin J Kaye A Levey E Pfeiffer M Sano CH van Dyck LJ Thal Alzheimer's Disease Cooperative Study Group 2005 Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2379 2388 (Pubitemid 40958434)
34. T Pirttila G Wilcock L Truyen CV Damaraju 2004 Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial Eur J Neurol 11 734 741 (Pubitemid 39556753)
35. MA Reger GS Watson PS Green CW Wilkinson LD Baker B Cholerton MA Fishel SR Plymate JC Breitner W DeGroodt P Mehta S Craft 2008 Intranasal insulin improves cognition and modulates beta-amyloid in early AD Neurology 70 440 448
36. K Ritchie S Artero J Touchon 2001 Classification criteria for mild cognitive impairment: a population-based validation study Neurology 56 37 42 (Pubitemid 32059649)
37. SL Rogers MR Farlow RS Doody R Mohs LT Friedhoff 1998 A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group Neurology 50 136 145 (Pubitemid 28106032)
38. M Rösler R Anand A Cicin-Sain S Gauthier Y Agid P Dal-Bianco HB Stähelin R Hartman M Gharabawi 1999 Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial BMJ 318 633 638 (Pubitemid 29192055)
39. MN Sabbagh MR Farlow N Relkin TG Beach 2006 Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimers Dement 2 118 125
40. S Salloway S Ferris A Kluger R Goldman T Griesing D Kumar S Richardson 2004 Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial Neurology 63 651 657 (Pubitemid 39100820)
41. AJ Saykin HA Wishart LA Rabin LA Flashman TL McHugh AC Mamourian RB Santulli 2004 Cholinergic enhancement of frontal lobe activity in mild cognitive impairment Brain 127 1574 1583 (Pubitemid 38899410)
42. GW Small D Kaufer MS Mendiondo P Quarg R Spiegel 2005 Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years Int J Clin Pract 59 473 477 (Pubitemid 40467894)
43. B Vellas S Andrieu C Sampaio N Coley G Wilcock for the European Task Force Group 2008 Endpoints for trials in Alzheimer's disease: a European task force consensus Lancet Neurol 7 436 450
44. PJ Visser P Sheltens FRJ Verhey 2005 Do MCI criteria in drug trials accurately identify subjects with pre-dementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 76 1348 1354 (Pubitemid 41360969)
45. JL Whitwell MM Shiung SA Przybelski SD Weigand DS Knopman BF Boeve RC Petersen CR Jack Jr 2008 MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment Neurology 70 512 520
46. GK Wilcock S Lilienfeld E Gaens 2000 Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group BMJ 321 1445 1449
47. DG Wilkinson AP Passmore R Bullock SW Hopker R Smith FC Potocnik CM Maud I Engelbrecht C Hock JR Ieni RS Bahra 2002 A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease Int J Clin Pract 56 441 446
48. A Wimo B Winblad L Jönsson 2007 An estimate of the total worldwide societal costs of dementia in 2005 Alzheimers Dement 3 81 91 (Pubitemid 46586163)
49. B Winblad S Gauthier L Scinto H Feldman GK Wilcock L Truyen AJ Mayorga D Wang HR Brashear JS Nye 2008 Safety and efficacy of galantamine in subjects with mild cognitive impairment Neurology 70 2024 2035
50. BA Wolf AM Wertkin YC Jolly RP Yasuda BB Wolfe RJ Konrad D Manning S Ravi JR Williamson VM Lee 1995 Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells J Biol Chem 270 4916 4922